Abstract
In the past decade, exciting therapeutic strategies to harness the ubiquitin-proteasome system (UPS) for degradation of target proteins have emerged. Proximity-inducing modalities are at the center of these strategies and act by modulating protein-protein interactions. While we are still learning to harvest this approach, it holds tremendous promise for developing treatments for hitherto undruggable proteins. Here, we discuss how academic efforts and academic-industrial collaboration have advanced the development of therapeutic modalities based on the principle of proximity induction. We make a case for forming a global academia-industry alliance to enhance access to training and expertise while accelerating innovation and translation from ground-breaking ideas to proof of concept in the clinic.
| Original language | English |
|---|---|
| Pages (from-to) | 3012-3022 |
| Number of pages | 11 |
| Journal | Molecular Cell |
| Volume | 85 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 21 Aug 2025 |
Keywords
- academic-industrial collaboration
- E3 ligases
- innovation hubs
- MGDs
- molecular glue degraders
- PROTACs
- proximity induction
- public-private partnerships
- targeted protein degradation
- technology transfer
- TPD
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology
Access to Document
- Final published version
Molecular Cell 85, August 21, 2025 © 2025 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).